Christine Jenkins's Publications

About Christine Jenkins's Publications

Program Head, Respiratory
  • Professor of Respiratory Medicine, Faculty of Medicine, UNSW Sydney
  • Clinical Professor, Concord Clinical School, University of Sydney
  • AM,
  • MD,
  • FRACP,
  • FThor ,
  • Soc ,
  • FAAHMS

  • Sodium cromoglycate in asthma

    Thorax Date published:

  • Markers of airway inflammation and airway hyperresponsiveness in patients with well-controlled asthma

    European Respiratory Journal Date published:

  • Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection withChlamydia pneumoniae

    American Journal of Respiratory and Critical Care Medicine Date published:

  • Estratégia global para o diagnóstico, manejo e prevenção da Doença Pulmonar Obstrutiva Crónica

    Revista Portuguesa de Pneumologia Date published:

  • Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

    American Journal of Respiratory and Critical Care Medicine Date published:

  • Predictive Markers of Asthma Exacerbation during Stepwise Dose Reduction of Inhaled Corticosteroids

    American Journal of Respiratory and Critical Care Medicine Date published:

  • Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): Executive summary

    Respiratory Care Date published:

  • A simple index of peak flow variation - longitudinal relationship with other markers of asthma control

    Respirology Date published:

  • Enhancing care for people with asthma: the role of communication, education, training and self-management

    European Respiratory Journal Date published:

  • Optimal asthma control, starting with high doses of inhaled budesonide

    European Respiratory Journal Date published:

  • Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μ g twice daily and budesonide 800 μ g twice daily in the treatment of adults and adolescents with asthma

    Respiratory Medicine Date published:

  • Salmeterol/fluticasone propionate combination therapy 50/250 μ g twice daily is more effective than budesonide 800 μ g twice daily in treating moderate to severe asthma

    Respiratory Medicine Date published:

  • Recommending Analgesics for People with Asthma

    American Journal of Therapeutics Date published:

  • Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma

    European Respiratory Journal Date published:

  • EUROPEAN RESPIRATORY JOURNAL

    Date published:

  • 493 Avair?/Seretide? (salmeterol 50mcg/fluticasone propionate 250 mcg bid) compared with budesonide (800 mcg bid) during the first week of treatment of moderate asthma

    Journal of Allergy and Clinical Immunology Date published: